Skip to main content

Eptifibatide Injection

Last Updated: November 29, 2022
Status: Current

Products Affected - Description
    • Eptifibatide injection, Amneal, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70121-1003-01
    • Eptifibatide injection, Amneal, 2 mg/mL, 10 mL vial, 1 count, NDC 70121-1002-01
    • Eptifibatide injection, Eugia US, 2 mg/mL, 100 mL vial, 1 count, NDC 55150-0220-99
    • Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 25021-0408-51
    • Eptifibatide injection, Sagent, 2 mg/mL, 10 mL vial, 1 count, NDC 25021-0409-10
    • Eptifibatide injection, Slate Run Pharmaceuticals, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70436-0027-80
    • Eptifibatide injection, Slate Run Pharmaceuticals, 2 mg/mL, 10 mL vial, 1 count, NDC 70436-0026-80
Reason for the Shortage
    • Accord has temporarily discontinued eptifibatide injection.
    • Akorn is not currently marketing eptifibatide.
    • Amneal did not provide a reason for the shortage.
    • Baxter has eptifibatide injection available.
    • Eugia did not provide a reason for the shortage.
    • Merck discontinued Integrilin in October 2020. Wholesalers may continue to sell inventory until product expires.
    • Viatris did not provide a reason for the shortage.
    • Sagent states the shortage is due to manufacturing delay.
    • Slate Run has eptifibatide injection available.
Available Products
    • Eptifibatide injection, Baxter, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00338-9558-10
    • Eptifibatide injection, Eugia US, 0.75 mg/mL, 100 mL vial, 1 count, NDC 55150-0218-99
    • Eptifibatide injection, Eugia US, 2 mg/mL, 10 mL vial, 1 count, NDC 55150-0219-10
    • Eptifibatide injection, Mylan Institutional (Viatris), 0.75 mg/mL, 100 mL vial, 1 count, NDC 67457-0631-10
    • Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 10 mL vial, 1 count, NDC 67457-0629-10
    • Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 100 mL vial, 1 count, NDC 67457-0630-10

Estimated Resupply Dates

    • Amneal has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on long-term back order and the company cannot estimate a release date.
    • Eugia has eptifibatide 2 mg/mL in 100 mL vials available with a short expiry of August 2023.
    • Sagent has eptifibatide 2 mg/mL in 10 mL vials on back order and the company cannot estimate a release date. The 0.75 mg/mL in 100 mL vials are available in limited allocation.
    • Slate Run has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on allocation.

Updated

Updated November 29, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 21, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer